Advertisement

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Peter Clark, MA, MD, FRCP: A Payer Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement

Sep

01

Today In Oncology

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country

Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy

Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy

Advertisement

© 2025 HSP News Service, L.L.C.